Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487391 | 0.94 | PDK2 (0.31) | MEN1MAPTKMT2AGAA | |
| SCHEMBL13487125 | 0.94 | TYMS (0.33) | TYMSMEN1MAPTKMT2AGAA | |
| SCHEMBL13487302 | 0.92 | AKT1 (0.38) | MEN1MAPTKMT2AGAAMAPK1 | |
| SCHEMBL13487197 | 0.91 | MEN1 (0.35) | MEN1MAPTKMT2AGAAMAPK1 | |
| SCHEMBL13487127 | 0.90 | TYMS (0.31) | TYMS | |
| SCHEMBL13487129 | 0.90 | TYMS (0.31) | TYMSKMT2ATSHR | |
| SCHEMBL13487132 | 0.90 | HSD17B3 (0.37) | TYMSKMT2ATSHRSMN1; SMN2 | |
| SCHEMBL13487131 | 0.90 | TYMS (0.31) | TYMS | |
| SCHEMBL13487130 | 0.89 | TYMS (0.31) | TYMS | |
| SCHEMBL13487126 | 0.89 | TYMS (0.31) | TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | TYMS 1763/4885MEN1 3017/4885MAPT 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.